FDA Approves Expanded Use of CRESEMBA(r) (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Source :: Plus Company Updates. December 11, 2023
Publication Year :: 2023
Abstract: NORTHBROOK, Ill: Astellas Pharma US, Inc. has issued the following news release: Astellas Pharma US, Inc. (President: Mark Reisenauer, 'Astellas') today announced that the U.S. Food and Drug Administration (FDA) [...]

Subjects :: United States. Food and Drug Administration
Astellas Pharma US, Inc.
Pediatrics -- Usage
Antifungal agents -- Usage
Children -- Health aspects
Drug approval -- Usage
Sulfates -- Usage
Aspergillosis -- Drug therapy
Mucormycosis -- Drug therapy
Pharmaceutical industry -- Usage
General interest
News, opinion and commentary
Cresemba (Medication) -- Usage

Tools